Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement
Incretin-based therapies have transformed obesity treatment, producing substantial weight loss and benefits across cardiometabolic outcomes. However, translating therapeutic efficacy into sustainable population-level benefit remains challenging across European healthcare systems that vary in workforce capability, multidisciplinary care, reimbursement, access, and monitoring infrastructure. We describe this mismatch as the EASO Integration Paradox: therapeutic innovation has advanced more rapidly than the health-system structures required for its optimal, equitable, and sustainable implementation. In this EASO Position Statement, we propose the EASO Integration Framework, a model for integrating incretin-based therapies into comprehensive obesity care. The framework is organized around five interdependent pillars: Right Patient, Right Care, Right Workforce, Right Data, and Right Access. We also outline a European research and implementation agenda focused on real-world evidence, harmonised monitoring, workforce development, pharmacovigilance, and equitable access. The challenge is no longer whether incretin-based therapies should be used, but how they should be implemented responsibly within comprehensive obesity care pathways.
Coûts des maladies transmissibles et non transmissibles ainsi que coûts des facteurs de risque que sont le surpoids/l'obésité et le manque d'activité physique en Suisse
L'étude calcule les coûts monétaires des maladies non transmissibles (MNT), des maladies transmissibles (MT) et de toutes les autres causes (maladies, blessures, etc.) en Suisse en 2012, 2017 et 2022.